Hearing Loss Trial, Recruiting NCT07024524 Sponsor: Eye & ENT Hospital of Fudan University Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT07024524
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • (For the hearing loss group) You were born with hearing loss, your hearing loss is significant (65 dB or greater), and you have already received hearing aids, a cochlear implant, or gene therapy for your hearing
  • (For the hearing loss group) You are between 1 and 35 years old, any gender
  • (For the healthy volunteer group) You have normal hearing (20 dB or better) and are a similar age and gender to someone in the hearing loss group
  • Your first/native language is Mandarin Chinese
  • You (and/or your parent or guardian) are willing to give written consent to take part and attend all required check-in appointments
  • You are able to communicate with the research team, with help from a guardian if needed, and are willing to follow the study's requirements
  • You (and/or your parent or guardian) have a realistic understanding of the trial and what it may or may not achieve

Who may not be able to join:

  • You have other ear or hearing conditions (such as middle ear infections or Meniere's disease) that could affect the study results
  • You have another serious condition you were born with, such as a heart defect
  • You have a serious ongoing illness or a disease that is currently flaring up, such as tuberculosis, active hepatitis B or C, active shingles, pancreatitis, or kidney problems
  • You have a weakened immune system, a diagnosed immune deficiency, or have had an organ transplant
  • You have a history of neurological or mental health conditions, or moderate-to-severe cognitive difficulties — for example epilepsy, dementia, or autism spectrum disorder
  • The trial team has any other reason to feel that joining would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 21 6437 7134

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Eye & ENT Hospital of Fudan University
Registry
ClinicalTrials.gov
Start date
4 July 2025
Est. completion
1 January 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Reliability; Reliability; Validity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov